Mikhail Mishustin: “This national project will be aimed at introducing new medical technologies, and assistance in clinical research and trials with subsequent registration and market launch of promising diagnostic and treatment methods, medicines, medical devices and products, including the products of regenerative biomedicine and tissue engineering.”
Mikhail Mishustin chairs strategic session on the national project New Health Saving Technologies
Mikhail Mishustin’s opening remarks:
Good afternoon, colleagues.
At this strategic session, we are going to discuss ways to maintain public health and increase active life expectancy in Russia. The President always highlights the importance of these policies.
This national project will be aimed at introducing new medical technologies, and assistance in clinical research and trials with subsequent registration and market launch of promising diagnostic and treatment methods, medicines, medical devices and products, including the products of regenerative biomedicine and tissue engineering.
The proposal is to include five federal projects under this umbrella project. They are aimed at developing medical science, creating new generation products, dosage forms and platforms, innovative biomedical and cognitive technologies, ultimately ensuring active and healthy longevity. They will definitely focus on establishing domestic production facilities to manufacture the above products locally. The industry has been demonstrating rapid growth this year, with the output of medicines and medical materials increasing by almost 8 percent in January-May. The national project in question is designed to support this trend.
In five years, we are to develop a mechanism for promoting the above products and solutions all the way from concept to rollout, so that people could take advantage of these new solutions and, accordingly, innovative treatments as soon as possible. We plan to support the development of 25 gene therapy drugs and personalised cell products, as well as 11 products enabled by artificial intelligence.
Plans are in place to develop 10 technologies aimed at preventing or correcting possible cognitive disorders. In addition, more than 15 biomedical solutions will be developed, some of them involving bioprinting. Ten new technologies will reduce the burden of cell aging. These will, inter alia, help determine and maintain the patient’s biological age, and enable proactive measures to prevent diseases and related risk factors.
As for the production facilities, during the period of the national project, we plan to increase the share of domestic production of vital and essential drugs to 90 percent, and up to 40 percent in case of medical devices. This, in turn, will contribute to Russia’s technological sovereignty in the field of pharma and the medical industry.
